Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

John Lazo

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Disorders

Concepts & Ideas

Kinetics

Phenomena

Phosphorylation

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Jiang Jianfei; McDonald Peter R; Dixon Tracy M; Franicola Darcy; Zhang Xichen; Nie Suhua; Epperly Laura D; Huang Zhentai; Kagan Valerian E; Lazo John S; Epperly Michael W; Greenberger Joel S
Synthetic protection short interfering RNA screen reveals glyburide as a novel radioprotector.
de Oliveira Pierre E Queiroz; Zhang Lin; Wang Zhenghe; Lazo John S
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21.
Molina Gabriela; Vogt Andreas; Bakan Ahmet; Dai Weixiang; Queiroz de Oliveira Pierre; Znosko Wade; Smithgall Thomas E; Bahar Ivet; Lazo John S; Day Billy W; Tsang Michael
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of John Lazo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Jiang Jianfei; McDonald Peter R; Dixon Tracy M; Franicola Darcy; Zhang Xichen; Nie Suhua; Epperly Laura D; Huang Zhentai; Kagan Valerian E; Lazo John S; Epperly Michael W; Greenberger Joel S
Synthetic protection short interfering RNA screen reveals glyburide as a novel radioprotector.
Radiation research 2009;172(4):414-22.
2009: de Oliveira Pierre E Queiroz; Zhang Lin; Wang Zhenghe; Lazo John S
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21.
Cell cycle (Georgetown, Tex.) 2009;8(19):3157-64.
2009: Molina Gabriela; Vogt Andreas; Bakan Ahmet; Dai Weixiang; Queiroz de Oliveira Pierre; Znosko Wade; Smithgall Thomas E; Bahar Ivet; Lazo John S; Day Billy W; Tsang Michael
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages.
Nature chemical biology 2009;5(9):680-7.
2009: Johnston Paul A; Foster Caleb A; Tierno Marni Brisson; Shun Tong Ying; Shinde Sunita N; Paquette William D; Brummond Kay M; Wipf Peter; Lazo John S
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
Assay and drug development technologies 2009;7(3):250-65.
2009: Vogt Andreas; Cholewinski Andrzej; Shen Xiaoqiang; Nelson Scott G; Lazo John S; Tsang Michael; Hukriede Neil A
Automated image-based phenotypic analysis in zebrafish embryos.
Developmental dynamics : an official publication of the American Association of Anatomists 2009;238(3):656-63.
2009: Mustata Gabriela; Follis Ariele Viacava; Hammoudeh Dalia I; Metallo Steven J; Wang Huabo; Prochownik Edward V; Lazo John S; Bahar Ivet
Discovery of novel myc-max heterodimer disruptors with a three-dimensional pharmacophore model.
Journal of medicinal chemistry 2009;52(5):1247-50.
2009: Tierno Marni Brisson; Kitchens Carolyn A; Petrik Bethany; Graham Thomas H; Wipf Peter; Xu Fengfeng L; Saunders William S; Raccor Brianne S; Balachandran Raghavan; Day Billy W; Stout Jane R; Walczak Claire E; Ducruet Alexander P; Reese Celeste E; Lazo John S
Microtubule binding and disruption and induction of premature senescence by disorazole C(1).
The Journal of pharmacology and experimental therapeutics 2009;328(3):715-22.
2009: Cao Shugeng; Murphy Brian T; Foster Caleb; Lazo John S; Kingston David G I
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.
Bioorganic & medicinal chemistry 2009;17(6):2276-81.
2009: Guo Jianxia; Parise Robert A; Joseph Erin; Egorin Merrill J; Lazo John S; Prochownik Edward V; Eiseman Julie L
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.
Cancer chemotherapy and pharmacology 2009;63(4):615-25.
2009: Tomko Robert J; Azang-Njaah Ndang N; Lazo John S
Nitrosative stress suppresses checkpoint activation after DNA synthesis inhibition.
Cell cycle (Georgetown, Tex.) 2009;8(2):299-305.
2009: Tasaki Takafumi; Zakrzewska Adriana; Dudgeon Drew D; Jiang Yonghua; Lazo John S; Kwon Yong Tae
The substrate recognition domains of the N-end rule pathway.
The Journal of biological chemistry 2009;284(3):1884-95.
2009: Sharlow Elizabeth R; Close David; Shun Tongying; Leimgruber Stephanie; Reed Robyn; Mustata Gabriela; Wipf Peter; Johnson Jacob; O'Neil Michael; Grögl Max; Magill Alan J; Lazo John S
Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen.
PLoS neglected tropical diseases 2009;3(11):e540.
2008: Lazo John S; Wipf Peter
Is Cdc25 a druggable target?
Anti-cancer agents in medicinal chemistry 2008;8(8):837-42.
2008: Sharlow Elizabeth R; Giridhar Karthik V; LaValle Courtney R; Chen Jun; Leimgruber Stephanie; Barrett Rebecca; Bravo-Altamirano Karla; Wipf Peter; Lazo John S; Wang Q Jane
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.
The Journal of biological chemistry 2008;283(48):33516-26.
2008: Keinan Shahar; Paquette William D; Skoko John J; Beratan David N; Yang Weitao; Shinde Sunita; Johnston Paul A; Lazo John S; Wipf Peter
Computational design, synthesis and biological evaluation of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B.
Organic & biomolecular chemistry 2008;6(18):3256-63.
2008: Tomko Robert J; Lazo John S
Multimodal control of Cdc25A by nitrosative stress.
Cancer research 2008;68(18):7457-65.
2008: Johnston Paul A; Soares Karina M; Shinde Sunita N; Foster Caleb A; Shun Tong Ying; Takyi Harold K; Wipf Peter; Lazo John S
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents.
Assay and drug development technologies 2008;6(4):505-18.
2008: Queiroz de Oliveira Pierre E; Tomko Robert J; Lazo John S
Is a step backwards in S-phase-targeted chemotherapy a step forward?
Molecular interventions 2008;8(3):137-40.
2008: Lazo John S
Rear-view mirrors and crystal balls: a brief reflection on drug discovery.
Molecular interventions 2008;8(2):60-3.
2008: Vogt Andreas; McDonald Peter R; Tamewitz Aletheia; Sikorski Rachel P; Wipf Peter; Skoko John J; Lazo John S
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells.
Molecular cancer therapeutics 2008;7(2):330-40.
2008: Bakan Ahmet; Lazo John S; Wipf Peter; Brummond Kay M; Bahar Ivet
Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.
Current medicinal chemistry 2008;15(25):2536-44.
2008: Sharlow Elizabeth R; Leimgruber Stephanie; Yellow-Duke Archibong; Barrett Rebecca; Wang Qiming Jane; Lazo John S
Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries.
Nature protocols 2008;3(8):1350-63.
2007: Johnston Paul A; Phillips Jennifer; Shun Tong Ying; Shinde Sunita; Lazo John S; Huryn Donna M; Myers Michael C; Ratnikov Boris I; Smith Jeffrey W; Su Ying; Dahl Russell; Cosford Nicholas D P; Shiryaev Sergey A; Strongin Alex Y
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus.
Assay and drug development technologies 2007;5(6):737-50.
2007: Sharlow Elizabeth R; Leimgruber Stephanie; Shun Tong Ying; Lazo John S
Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1.
Assay and drug development technologies 2007;5(6):723-35.
2007: Srivastava Sanjay K; Bansal Pallavi; Oguri Tetsuya; Lazo John S; Singh Shivendra V
Cell division cycle 25B phosphatase is essential for benzo(a)pyrene-7,8-Diol-9,10-epoxide induced neoplastic transformation.
Cancer research 2007;67(19):9150-7.
2007: Guo Jianxia; Parise Robert A; Joseph Erin; Lan Jing; Pan Su-Shu; Joo Beomjun; Egorin Merrill J; Wipf Peter; Lazo John S; Eiseman Julie L
Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284).
Anticancer research 2007;27(5A):3067-73.
2007: Wang Huabo; Hammoudeh Dalia I; Follis Ariele Viacava; Reese Brian E; Lazo John S; Metallo Steven J; Prochownik Edward V
Improved low molecular weight Myc-Max inhibitors.
Molecular cancer therapeutics 2007;6(9):2399-408.
2007: Lazo John S; Skoko John J; Werner Stefan; Mitasev Branko; Bakan Ahmet; Koizumi Fumito; Yellow-Duke Archibong; Bahar Ivet; Brummond Kay M
Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboxamide library.
The Journal of pharmacology and experimental therapeutics 2007;322(3):940-7.
2007: Lazo John S
Pharmacology goes phlat: molecular interventions feels the impact.
Molecular interventions 2007;7(4):178.
2007: Vogt Andreas; Lazo John S
Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases.
Methods (San Diego, Calif.) 2007;42(3):268-77.
2007: Lazo John S; Brady Linda S; Dingledine Ray
Building a pharmacological lexicon: small molecule discovery in academia.
Molecular pharmacology 2007;72(1):1-7.
2007: Johnston Paul A; Foster Caleb A; Shun Tong Ying; Skoko John J; Shinde Sunita; Wipf Peter; Lazo John S
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.
Assay and drug development technologies 2007;5(3):319-32.
2007: Towne Charles F; York Ian A; Watkin Levi B; Lazo John S; Rock Kenneth L
Analysis of the role of bleomycin hydrolase in antigen presentation and the generation of CD8 T cell responses.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(11):6923-30.
2007: Montoya S E; Thiels E; Card J P; Lazo J S
Astrogliosis and behavioral changes in mice lacking the neutral cysteine protease bleomycin hydrolase.
Neuroscience 2007;146(3):890-900.
2007: Bansal Pallavi; Lazo John S
Induction of Cdc25B regulates cell cycle resumption after genotoxic stress.
Cancer research 2007;67(7):3356-63.
2007: Lazo John S
In the forefront of basic and translational cancer research - 7th AACR-JCA Joint International Conference.
IDrugs : the investigational drugs journal 2007;10(4):224-6.
2007: Panchal Rekha G; Ruthel Gordon; Brittingham Katherine C; Lane Douglas; Kenny Tara A; Gussio Rick; Lazo John S; Bavari Sina
Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis.
Chemistry & biology 2007;14(3):245-55.
2007: Arnold David M; Foster Caleb; Huryn Donna M; Lazo John S; Johnston Paul A; Wipf Peter
Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors.
Chemical biology & drug design 2007;69(1):23-30.
2007: Achiwa Hiroyuki; Lazo John S
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.
Cancer research 2007;67(2):643-50.
2007: Brisson Marni; Foster Caleb; Wipf Peter; Joo Beomjun; Tomko Robert J; Nguyen Theresa; Lazo John S
Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone.
Molecular pharmacology 2007;71(1):184-92.
2007: Tierno Marni Brisson; Johnston Paul A; Foster Caleb; Skoko John J; Shinde Sunita N; Shun Tong Ying; Lazo John S
Development and optimization of high-throughput in vitro protein phosphatase screening assays.
Nature protocols 2007;2(5):1134-44.
2007: Vogt Andreas; Lazo John S
Discovery of protein kinase phosphatase inhibitors.
Methods in molecular biology (Clifton, N.J.) 2007;356():389-400.
2006: Lazo John S
Roadmap or roadkill: a pharmacologist's analysis of the NIH Molecular Libraries Initiative.
Molecular interventions 2006;6(5):240-3.
2006: Cossy Janine; Belotti Damien; Brisson Marni; Skoko John J; Wipf Peter; Lazo John S
Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors.
Bioorganic & medicinal chemistry 2006;14(18):6283-7.
2006: Lazo John S; Nunes Ruth; Skoko John J; Queiroz de Oliveira Pierre E; Vogt Andreas; Wipf Peter
Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1.
Bioorganic & medicinal chemistry 2006;14(16):5643-50.
2006: Tomko Robert J; Bansal Pallavi; Lazo John S
Airing out an antioxidant role for the tumor suppressor p53.
Molecular interventions 2006;6(1):23-5, 2.
2006: Wipf Peter; Graham Thomas H; Vogt Andreas; Sikorski Rachel P; Ducruet Alexander P; Lazo John S
Cellular analysis of disorazole C and structure-activity relationship of analogs of the natural product.
Chemical biology & drug design 2006;67(1):66-73.
2005: Brisson Marni; Nguyen Theresa; Wipf Peter; Joo Beomjun; Day Billy W; Skoko John S; Schreiber Emanuel M; Foster Caleb; Bansal Pallavi; Lazo John S
Redox regulation of Cdc25B by cell-active quinolinediones.
Molecular pharmacology 2005;68(6):1810-20.
2005: Lazo John S
Live long and prosper.
Molecular pharmacology 2005;68(5):1193-5.
2005: Giuliano Kenneth A; Cheung Wing S; Curran Dennis P; Day Billy W; Kassick Andrew J; Lazo John S; Nelson Scott G; Shin Youseung; Taylor D Lansing
Systems cell biology knowledge created from high content screening.
Assay and drug development technologies 2005;3(5):501-14.
2005: Cao Shugeng; Foster Caleb; Lazo John S; Kingston David G I
Four diterpenoid inhibitors of Cdc25B phosphatase from a marine anemone.
Bioorganic & medicinal chemistry 2005;13(20):5830-4.
2005: Xiao Dong; Herman-Antosiewicz Anna; Antosiewicz Jedrzej; Xiao Hui; Brisson Marni; Lazo John S; Singh Shivendra V
Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C.
Oncogene 2005;24(41):6256-68.
2005: Cao Shugeng; Foster Caleb; Lazo John S; Kingston David G I
Sesterterpenoids and an alkaloid from a Thorectandra sp. as inhibitors of the phosphatase Cdc25B.
Bioorganic & medicinal chemistry 2005;13(17):5094-8.
2005: Vogt Andreas; Lazo John S
Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets.
Pharmacology & therapeutics 2005;107(2):212-21.
2005: Vasudevan Sanjeev A; Skoko John; Wang Kuan; Burlingame Susan M; Patel Parul N; Lazo John S; Nuchtern Jed G; Yang Jianhua
MKP-8, a novel MAPK phosphatase that inhibits p38 kinase.
Biochemical and biophysical research communications 2005;330(2):511-8.
2005: Vogt Andreas; Tamewitz Aletheia; Skoko John; Sikorski Rachel P; Giuliano Kenneth A; Lazo John S
The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1.
The Journal of biological chemistry 2005;280(19):19078-86.
2005: Cao Shugeng; Foster Caleb; Brisson Marni; Lazo John S; Kingston David G I
Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp.
Bioorganic & medicinal chemistry 2005;13(4):999-1003.
2005: Koldamova Radosveta P; Lefterov Iliya M; Staufenbiel Matthias; Wolfe Darren; Huang Shaohua; Glorioso Joseph C; Walter Michael; Roth Michael G; Lazo John S
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.
The Journal of biological chemistry 2005;280(6):4079-88.
2005: Ducruet Alexander P; Vogt Andreas; Wipf Peter; Lazo John S
Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease.
Annual review of pharmacology and toxicology 2005;45():725-50.
2004: Oguri Tetsuya; Nemoto Kaoru; Bansal Pallavi; Wipf Peter; Lazo John S
Induction of Cdc25B expression by epidermal growth factor and transforming growth factor-alpha.
Biochemical pharmacology 2004;68(11):2221-7.
2004: Cao Shugeng; Gao Zhijie; Thomas Shannon J; Hecht Sidney M; Lazo John S; Kingston David G I
Marine sesquiterpenoids that inhibit the lyase activity of DNA polymerase beta.
Journal of natural products 2004;67(10):1716-8.
2004: Brisson Marni; Nguyen Theresa; Vogt Andreas; Yalowich Jack; Giorgianni Angela; Tobi Dror; Bahar Ivet; Stephenson Corey R J; Wipf Peter; Lazo John S
Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
Molecular pharmacology 2004;66(4):824-33.
2004: Wipf Peter; Joo Beomjun; Nguyen Theresa; Lazo John S
Synthesis and biological evaluation of caulibugulones A-E.
Organic & biomolecular chemistry 2004;2(15):2173-4.
2004: Han Yusheng; Shen Hongmei; Carr Brian I; Wipf Peter; Lazo John S; Pan Su-shu
NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
The Journal of pharmacology and experimental therapeutics 2004;309(1):64-70.
2004: Nemoto Kaoru; Vogt Andreas; Oguri Tetsuya; Lazo John S
Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells.
The Prostate 2004;58(1):95-102.
2004: Vogt Andreas; Kalb Erica N; Lazo John S
A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity.
Oncology research 2004;14(6):305-14.
2003: Yin Xiaoying; Giap Christine; Lazo John S; Prochownik Edward V
Low molecular weight inhibitors of Myc-Max interaction and function.
Oncogene 2003;22(40):6151-9.
2003: Kar Siddhartha; Lefterov Iliya M; Wang Meifang; Lazo John S; Scott Colleen N; Wilcox Craig S; Carr Brian I
Binding and inhibition of Cdc25 phosphatases by vitamin K analogues.
Biochemistry 2003;42(35):10490-7.
2003: Vogt Andreas; Cooley Kathleen A; Brisson Marni; Tarpley Michael G; Wipf Peter; Lazo John S
Cell-active dual specificity phosphatase inhibitors identified by high-content screening.
Chemistry & biology 2003;10(8):733-42.
2003: Lazo John S; Ducruet Alexander P; Koldamova Radosevda P
Sleuthful pharmacology.
Molecular pharmacology 2003;64(2):199-201.
2003: Ducruet Alexander P; Lazo John S
Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity.
The Journal of biological chemistry 2003;278(34):31838-42.
2003: Lazo John S
Desperately seeking genotype-selective anticancer agents.
Chemistry & biology 2003;10(6):477-8.
2003: Koldamova Radosveta P; Lefterov Iliya M; Ikonomovic Milos D; Skoko John; Lefterov Preslav I; Isanski Barbara A; DeKosky Steven T; Lazo John S
22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion.
The Journal of biological chemistry 2003;278(15):13244-56.
2003: Oguri Tetsuya; Singh Shivendra V; Nemoto Kaoru; Lazo John S
The carcinogen (7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene induces Cdc25B expression in human bronchial and lung cancer cells.
Cancer research 2003;63(4):771-5.
2003: Carr Brian I; Wang Ziqiu; Wang Meifang; Kar Siddhartha; Wilcox Craig S; Rosi Katharyn; Southwick Eileen; Lazo John S
A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo.
Journal of molecular biology 2003;326(3):721-35.
2003: Lazo John S; Wipf Peter
Small molecule regulation of phosphatase-dependent cell signaling pathways.
Oncology research 2003;13(6-10):347-52.
2002: Lyon Michael A; Ducruet Alexander P; Wipf Peter; Lazo John S
Dual-specificity phosphatases as targets for antineoplastic agents.
Nature reviews. Drug discovery 2002;1(12):961-76.
2002: Pu Lixia; Amoscato Andrew A; Bier Mark E; Lazo John S
Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione.
The Journal of biological chemistry 2002;277(49):46877-85.
2002: Vogt Andreas; Pestell Katharine E; Day Billy W; Lazo John S; Wipf Peter
The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity.
Molecular cancer therapeutics 2002;1(11):885-92.
2002: Hickman John A; Lazo John S
Changes and challenges--the world post-Gleevec (Glivec).
Current opinion in pharmacology 2002;2(4):357-60.
2002: Hashash Ahmad; Kirkpatrick D Lynn; Lazo John S; Block Lawrence H
Solubility, ionization, and partitioning behavior of unsymmetrical disulfide compounds: alkyl 2-imidazolyl disulfides.
Journal of pharmaceutical sciences 2002;91(7):1686-92.
2002: Wang Ziqiu; Wang Meifang; Lazo John S; Carr Brian I
Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase.
The Journal of biological chemistry 2002;277(22):19470-5.
2002: Lazo John S; Nemoto Kaoru; Pestell Katharine E; Cooley Kathleen; Southwick Eileen C; Mitchell Douglas A; Furey William; Gussio Rick; Zaharevitz Daniel W; Joo Beomjun; Wipf Peter
Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
Molecular pharmacology 2002;61(4):720-8.
2002: Hashash Ahmad; Kirkpatrick D Lynn; Egorin Merrill J; Block Lawrence H; Lazo John S
Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;768(2):239-46.
2001: Lazo J S; Aslan D C; Southwick E C; Cooley K A; Ducruet A P; Joo B; Vogt A; Wipf P
Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.
Journal of medicinal chemistry 2001;44(24):4042-9.
2001: Wang Z; Southwick E C; Wang M; Kar S; Rosi K S; Wilcox C S; Lazo J S; Carr B I
Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
Cancer research 2001;61(19):7211-6.
2001: Wipf P; Hopkins T D; Jung J K; Rodriguez S; Birmingham A; Southwick E C; Lazo J S; Powis G
New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead.
Bioorganic & medicinal chemistry letters 2001;11(19):2637-41.
2001: Vogt A; Adachi T; Ducruet A P; Chesebrough J; Nemoto K; Carr B I; Lazo J S
Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases.
The Journal of biological chemistry 2001;276(23):20544-50.
2001: Lefterov I M; Koldamova R P; Lefterova M I; Schwartz D R; Lazo J S
Cysteine 73 in bleomycin hydrolase is critical for amyloid precursor protein processing.
Biochemical and biophysical research communications 2001;283(4):994-9.
2001: Koldamova R P; Lefterov I M; Lefterova M I; Lazo J S
Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity.
Biochemistry 2001;40(12):3553-60.
2001: Wipf P; Aslan D C; Southwick E C; Lazo J S
Sulfonylated aminothiazoles as new small molecule inhibitors of protein phosphatases.
Bioorganic & medicinal chemistry letters 2001;11(3):313-7.
2001: Lazo J S; Tamura K; Vogt A; Jung J K; Rodriguez S; Balachandran R; Day B W; Wipf P
Antimitotic actions of a novel analog of the fungal metabolite palmarumycin CP1.
The Journal of pharmacology and experimental therapeutics 2001;296(2):364-71.
2000: Pestell K E; Ducruet A P; Wipf P; Lazo J S
Small molecule inhibitors of dual specificity protein phosphatases.
Oncogene 2000;19(56):6607-12.
2000: Liu S X; Fabisiak J P; Tyurin V A; Borisenko G G; Pitt B R; Lazo J S; Kagan V E
Reconstitution of apo-superoxide dismutase by nitric oxide-induced copper transfer from metallothioneins.
Chemical research in toxicology 2000;13(9):922-31.
2000: Lefterov I M; Koldamova R P; Lazo J S
Human bleomycin hydrolase regulates the secretion of amyloid precursor protein.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(12):1837-47.
2000: Vogt A; Tamura K; Watson S; Lazo J S
Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1.
The Journal of pharmacology and experimental therapeutics 2000;294(3):1070-5.
2000: Ducruet A P; Rice R L; Tamura K; Yokokawa F; Yokokawa S; Wipf P; Lazo J S
Identification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array.
Bioorganic & medicinal chemistry 2000;8(6):1451-66.
2000: Lazo J S; Wipf P
Combinatorial chemistry and contemporary pharmacology.
The Journal of pharmacology and experimental therapeutics 2000;293(3):705-9.
2000: Tamura K; Southwick E C; Kerns J; Rosi K; Carr B I; Wilcox C; Lazo J S
Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue.
Cancer research 2000;60(5):1317-25.
2000: Vogt A; Wang A S; Johnson C S; Fabisiak J P; Wipf P; Lazo J S
In vivo antitumor activity and induction of insulin-like growth factor-1-resistant apoptosis by SC-alphaalphadelta9.
The Journal of pharmacology and experimental therapeutics 2000;292(2):530-7.
2000: Fabisiak J P; Tyurin V A; Tyurina Y Y; Sedlov A; Lazo J S; Kagan V E
Nitric oxide dissociates lipid oxidation from apoptosis and phosphatidylserine externalization during oxidative stress.
Biochemistry 2000;39(1):127-38.
2000: Woo E S; Dellapiazza D; Wang A S; Lazo J S
Energy-dependent nuclear binding dictates metallothionein localization.
Journal of cellular physiology 2000;182(1):69-76.
2000: Wipf P; Aslan D C; Luci D K; Southwick E C; Lazo J S
Synthesis and biological evaluation of a targeted library of protein phosphatase inhibitors.
Biotechnology and bioengineering 2000;71(1):58-70.
1999: Tamura K; Rice R L; Wipf P; Lazo J S
Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor.
Oncogene 1999;18(50):6989-96.
1999: Kondo Y; Himeno S; Endo W; Mita M; Suzuki Y; Nemoto K; Akimoto M; Lazo J S; Imura N
Metallothionein modulates the carcinogenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine in mice.
Carcinogenesis 1999;20(8):1625-7.
1999: Schor N F; Tyurina Y Y; Fabisiak J P; Tyurin V A; Lazo J S; Kagan V E
Selective oxidation and externalization of membrane phosphatidylserine: Bcl-2-induced potentiation of the final common pathway for apoptosis.
Brain research 1999;831(1-2):125-30.
1999: Koldamova R P; Lefterov I M; DiSabella M T; Almonte C; Watkins S C; Lazo J S
Human bleomycin hydrolase binds ribosomal proteins.
Biochemistry 1999;38(22):7111-7.
1999: Woo E S; Rice R L; Lazo J S
Cell cycle dependent subcellular distribution of Cdc25B subtypes.
Oncogene 1999;18(17):2770-6.
1999: Schwartz D R; Homanics G E; Hoyt D G; Klein E; Abernethy J; Lazo J S
The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(8):4680-5.
1999: Fabisiak J P; Tyurin V A; Tyurina Y Y; Borisenko G G; Korotaeva A; Pitt B R; Lazo J S; Kagan V E
Redox regulation of copper-metallothionein.
Archives of biochemistry and biophysics 1999;363(1):171-81.
1999: Bredel M; Pollack I F; Freund J M; Rusnak J; Lazo J S
Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion.
Journal of neuro-oncology 1999;41(1):9-20.
1999: Fabisiak J P; Pearce L L; Borisenko G G; Tyhurina Y Y; Tyurin V A; Razzack J; Lazo J S; Pitt B R; Kagan V E
Bifunctional anti/prooxidant potential of metallothionenin: redox signaling of copper binding and release.
Antioxidants & redox signaling 1999;1(3):349-64.
1999: Lazo J S
Bleomycin.
Cancer chemotherapy and biological response modifiers 1999;18():39-45.
1999: Kondo Y; Yanagiya T; Himeno S; Yamabe Y; Schwartz D; Akimoto M; Lazo J S; Imura N
Simian virus 40-transformed metallothionein null cells showed increased sensitivity to cadmium but not to zinc, copper, mercury or nickel.
Life sciences 1999;64(11):PL145-50.
1998: Koldamova R P; Lefterov I M; DiSabella M T; Lazo J S
An evolutionarily conserved cysteine protease, human bleomycin hydrolase, binds to the human homologue of ubiquitin-conjugating enzyme 9.
Molecular pharmacology 1998;54(6):954-61.
1998: Vogt A; Rice R L; Settineri C E; Yokokawa F; Yokokawa S; Wipf P; Lazo J S
Disruption of insulin-like growth factor-1 signaling and down-regulation of cdc2 by SC-alphaalphadelta9, a novel small molecule antisignaling agent identified in a targeted array library.
The Journal of pharmacology and experimental therapeutics 1998;287(2):806-13.
1998: Lefterov I M; Koldamova R P; King J; Lazo J S
The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage.
Mutation research 1998;421(1):1-7.
1998: Fabisiak J P; Tyurina Y Y; Tyurin V A; Lazo J S; Kagan V E
Random versus selective membrane phospholipid oxidation in apoptosis: role of phosphatidylserine.
Biochemistry 1998;37(39):13781-90.
1998: Fabisiak J P; Kagan V E; Tyurina Y Y; Tyurin V A; Lazo J S
Paraquat-induced phosphatidylserine oxidation and apoptosis are independent of activation of PLA2.
The American journal of physiology 1998;274(5 Pt 1):L793-802.
1998: Lazo J S; Kuo S M; Woo E S; Pitt B R
The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs.
Chemico-biological interactions 1998;111-112():255-62.
1998: Montoya S E; Aston C E; DeKosky S T; Kamboh M I; Lazo J S; Ferrell R E
Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease.
Nature genetics 1998;18(3):211-2.
1998: Koldamova R P; Lefterov I M; Gadjeva V G; Lazo J S
Essential binding and functional domains of human bleomycin hydrolase.
Biochemistry 1998;37(8):2282-90.
1998: Yang Y Y; Robbins P D; Lazo J S
Differential transactivation of human metallothionein-IIa in cisplatin-resistant and -sensitive cells.
Oncology research 1998;10(2):85-98.
1997: Rice R L; Rusnak J M; Yokokawa F; Yokokawa S; Messner D J; Boynton A L; Wipf P; Lazo J S
A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation.
Biochemistry 1997;36(50):15965-74.
1997: Pitt B R; Schwarz M; Woo E S; Yee E; Wasserloos K; Tran S; Weng W; Mannix R J; Watkins S A; Tyurina Y Y; Tyurin V A; Kagan V E; Lazo J S
Overexpression of metallothionein decreases sensitivity of pulmonary endothelial cells to oxidant injury.
The American journal of physiology 1997;273(4 Pt 1):L856-65.
1997: Woo E S; Lazo J S
Nucleocytoplasmic functionality of metallothionein.
Cancer research 1997;57(19):4236-41.
1997: Montoya S E; Ferrell R E; Lazo J S
Genomic structure and genetic mapping of the human neutral cysteine protease bleomycin hydrolase.
Cancer research 1997;57(19):4191-5.
1997: Hoyt D G; Rizzo M; Gerritsen M E; Pitt B R; Lazo J S
Integrin activation protects pulmonary endothelial cells from the genotoxic effects of bleomycin.
The American journal of physiology 1997;273(3 Pt 1):L612-7.
1997: Kondo Y; Rusnak J M; Hoyt D G; Settineri C E; Pitt B R; Lazo J S
Enhanced apoptosis in metallothionein null cells.
Molecular pharmacology 1997;52(2):195-201.
1997: Lazo J S; Li T; Woo E S; Settineri C E; Allan W P; Yalowich J C
Chemical synthesis and biological activity of a novel fluorescent etoposide derivative.
Biochemical pharmacology 1997;53(5):715-22.
1997: Fabisiak J P; Kagan V E; Ritov V B; Johnson D E; Lazo J S
Bcl-2 inhibits selective oxidation and externalization of phosphatidylserine during paraquat-induced apoptosis.
The American journal of physiology 1997;272(2 Pt 1):C675-84.
1997: Wipf P; Cunningham A; Rice R L; Lazo J S
Combinatorial synthesis and biological evaluation of library of small-molecule Ser/Thr-protein phosphatase inhibitors.
Bioorganic & medicinal chemistry 1997;5(1):165-77.
1997: Lazo J S; Sebti S M
Bleomycin.
Cancer chemotherapy and biological response modifiers 1997;17():40-5.
1997: Woo E S; Monks A; Watkins S C; Wang A S; Lazo J S
Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel.
Cancer chemotherapy and pharmacology 1997;41(1):61-8.
1996: Wong H R; Mannix R J; Rusnak J M; Boota A; Zar H; Watkins S C; Lazo J S; Pitt B R
The heat-shock response attenuates lipopolysaccharide-mediated apoptosis in cultured sheep pulmonary artery endothelial cells.
American journal of respiratory cell and molecular biology 1996;15(6):745-51.
1996: Wipf P; Li W; Adeyeye C M; Rusnak J M; Lazo J S
Synthesis of chemoreversible prodrugs of ara-C with variable time-release profiles. Biological evaluation of their apoptotic activity.
Bioorganic & medicinal chemistry 1996;4(10):1585-96.
1996: Hoyt D G; Rusnak J M; Mannix R J; Modzelewski R A; Johnson C S; Lazo J S
Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells.
Cancer research 1996;56(18):4146-9.
1996: Pollack I F; Kawecki S; Lazo J S
Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Journal of neurosurgery 1996;84(6):1024-32.
1996: Woo E S; Kondo Y; Watkins S C; Hoyt D G; Lazo J S
Nucleophilic distribution of metallothionein in human tumor cells.
Experimental cell research 1996;224(2):365-71.
1996: Hoyt D G; Mannix R J; Gerritsen M E; Watkins S C; Lazo J S; Pitt B R
Integrins inhibit LPS-induced DNA strand breakage in cultured lung endothelial cells.
The American journal of physiology 1996;270(4 Pt 1):L689-94.
1996: Rusnak J M; Lazo J S
Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells.
Experimental cell research 1996;224(1):189-99.
1996: Huang L; Son K; Gao X; Hages D; Yang Y Y; Holden S A; Teicher B; Kirkwood J; Lazo J S
Efficient lipofection with cisplatin-resistant human tumor cells.
Cancer gene therapy 1996;3(2):107-12.
1996: Rusnak J M; Calmels T P; Hoyt D G; Kondo Y; Yalowich J C; Lazo J S
Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
Molecular pharmacology 1996;49(2):244-52.
1996: Lazo J S; Sebti S M; Schellens J H
Bleomycin.
Cancer chemotherapy and biological response modifiers 1996;16():39-47.
1995: Hoyt D G; Mannix R J; Rusnak J M; Pitt B R; Lazo J S
Collagen is a survival factor against LPS-induced apoptosis in cultured sheep pulmonary artery endothelial cells.
The American journal of physiology 1995;269(2 Pt 1):L171-7.
1995: Kondo Y; Woo E S; Michalska A E; Choo K H; Lazo J S
Metallothionein null cells have increased sensitivity to anticancer drugs.
Cancer research 1995;55(10):2021-3.
1995: Schwarz M A; Lazo J S; Yalowich J C; Allen W P; Whitmore M; Bergonia H A; Tzeng E; Billiar T R; Robbins P D; Lancaster J R
Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(10):4452-6.
1995: Lazo J S; Kondo Y; Dellapiazza D; Michalska A E; Choo K H; Pitt B R
Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes.
The Journal of biological chemistry 1995;270(10):5506-10.
1995: Kondo Y; Kuo S M; Watkins S C; Lazo J S
Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines.
Cancer research 1995;55(3):474-7.
1995: Lazo J S; Pitt B R
Metallothioneins and cell death by anticancer drugs.
Annual review of pharmacology and toxicology 1995;35():635-53.
1994: Hoyt D G; Lazo J S
Acute pneumocyte injury, poly(ADP-ribose) polymerase activity, and pyridine nucleotide levels after in vitro exposure of murine lung slices to cyclophosphamide.
Biochemical pharmacology 1994;48(9):1757-65.
1994: Ritke M K; Rusnak J M; Lazo J S; Allan W P; Dive C; Heer S; Yalowich J C
Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
Molecular pharmacology 1994;46(4):605-11.
1994: Kondo Y; Kuo S M; Lazo J S
Interleukin-1 beta-mediated metallothionein induction and cytoprotection against cadmium and cis-diamminedichloroplatinum.
The Journal of pharmacology and experimental therapeutics 1994;270(3):1313-8.
1994: Hait W N; Gesmonde J F; Lazo J S
Effect of anti-calmodulin drugs on the growth and sensitivity of C6 rat glioma cells to bleomycin.
Anticancer research 1994;14(5A):1711-21.
1994: Schwarz M A; Lazo J S; Yalowich J C; Reynolds I; Kagan V E; Tyurin V; Kim Y M; Watkins S C; Pitt B R
Cytoplasmic metallothionein overexpression protects NIH 3T3 cells from tert-butyl hydroperoxide toxicity.
The Journal of biological chemistry 1994;269(21):15238-43.
1994: Cherian M G; Howell S B; Imura N; Klaassen C D; Koropatnick J; Lazo J S; Waalkes M P
Role of metallothionein in carcinogenesis.
Toxicology and applied pharmacology 1994;126(1):1-5.
1994: Farhood H; Gao X; Son K; Yang Y Y; Lazo J S; Huang L; Barsoum J; Bottega R; Epand R M
Cationic liposomes for direct gene transfer in therapy of cancer and other diseases.
Annals of the New York Academy of Sciences 1994;716():23-34; discussion 34-5.
1994: Evans R R; Calmels T P; Pitt B R; Brookens M A; Johnson C S; Modzelewski R A; Lazo J S
Gene therapy and endothelial cell targeting for cancer.
Annals of the New York Academy of Sciences 1994;716():257-64.
1994: Yang Y Y; Woo E S; Reese C E; Bahnson R R; Saijo N; Lazo J S
Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells.
Molecular pharmacology 1994;45(3):453-60.
1994: Kuo S M; Kondo Y; DeFilippo J M; Ernstoff M S; Bahnson R R; Lazo J S
Subcellular localization of metallothionein IIA in human bladder tumor cells using a novel epitope-specific antiserum.
Toxicology and applied pharmacology 1994;125(1):104-10.
1994: Piedboeuf B; Johnston C J; Watkins R H; Hudak B B; Lazo J S; Cherian M G; Horowitz S
Increased expression of tissue inhibitor of metalloproteinases (TIMP-I) and metallothionein in murine lungs after hyperoxic exposure.
American journal of respiratory cell and molecular biology 1994;10(2):123-32.
1994: Lazo J S; Sebti S M
Bleomycin.
Cancer chemotherapy and biological response modifiers 1994;15():44-50.
1993: Calmels T P; Mistry J S; Watkins S C; Robbins P D; McGuire R; Lazo J S
Nuclear localization of bacterial Streptoalloteichus hindustanus bleomycin resistance protein in mammalian cells.
Molecular pharmacology 1993;44(6):1135-41.
1993: Hoyt D G; Lazo J S
NAD depletion after in vitro exposure of murine lung slices to bleomycin.
Biochemical pharmacology 1993;46(10):1819-24.
1993: Shellard S A; Fichtinger-Schepman A M; Lazo J S; Hill B T
Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
Anti-cancer drugs 1993;4(4):491-500.
1993: Mistry J S; Koepsel R R; Lazo J S
Structural basis for the sequence selectivity of DNA cleavage by bleomycins.
Biochemical and biophysical research communications 1993;191(2):420-6.
1993: Lazo J S; Sebti S M
Bleomycins.
Cancer chemotherapy and biological response modifiers 1993;14():37-44.
1992: Hoyt D G; Lazo J S
Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin.
American journal of respiratory cell and molecular biology 1992;7(6):645-51.
1992: Pitt B R; Brookens M A; Steve A R; Atlas A B; Davies P; Kuo S M; Lazo J S
Expression of pulmonary metallothionein genes in late gestational lambs.
Pediatric research 1992;32(4):424-30.
1992: Morris G; Mistry J S; Jani J P; Mignano J E; Sebti S M; Lazo J S
Neutralization of bleomycin hydrolase by an epitope-specific antibody.
Molecular pharmacology 1992;42(1):57-62.
1992: Basu A; Lazo J S
Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.
Cancer research 1992;52(11):3119-24.
1992: Jani J P; Mistry J S; Morris G; Davies P; Lazo J S; Sebti S M
In vivo circumvention of human colon carcinoma resistance to bleomycin.
Cancer research 1992;52(10):2931-7.
1992: Basu A; Kozikowski A P; Lazo J S
Structural requirements of lyngbyatoxin A for activation and downregulation of protein kinase C.
Biochemistry 1992;31(15):3824-30.
1992: Mistry J S; Jani J P; Morris G; Mujumdar R B; Reynolds I J; Sebti S M; Lazo J S
Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b.
Cancer research 1992;52(3):709-18.
1992: Lazo J S; Sebti S M
Bleomycins.
Cancer chemotherapy and biological response modifiers 1992;13():53-8.
1992: Jani J P; Mistry J S; Morris G; Lazo J S; Sebti S M
In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64.
Oncology research 1992;4(2):59-63.
1991: Bahnson R R; Banner B F; Ernstoff M S; Lazo J S; Cherian M G; Banerjee D; Chin J L
Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder.
The Journal of urology 1991;146(6):1518-20.
1991: Isonishi S; Hom D K; Thiebaut F B; Mann S C; Andrews P A; Basu A; Lazo J S; Eastman A; Howell S B
Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin.
Cancer research 1991;51(21):5903-9.
1991: Lazo J S; Basu A
Metallothionein expression and transient resistance to electrophilic antineoplastic drugs.
Seminars in cancer biology 1991;2(4):267-71.
1991: Kozikowski A P; Shum P W; Basu A; Lazo J S
Synthesis of structural analogues of lyngbyatoxin A and their evaluation as activators of protein kinase C.
Journal of medicinal chemistry 1991;34(8):2420-30.
1991: Filderman A E; Lazo J S
Murine strain differences in pulmonary bleomycin metabolism.
Biochemical pharmacology 1991;42(1):195-8.
1991: Morris G; Mistry J S; Jani J P; Sebti S M; Lazo J S
Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells.
Biochemical pharmacology 1991;41(11):1559-66.
1991: Basu A; Kozikowski A P; Sato K; Lazo J S
Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogues of the protein kinase C activator lyngbyatoxin A.
Cancer research 1991;51(10):2511-4.
1991: Basu A; Lazo J S
Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum(II) resistance by v-mos.
Cancer research 1991;51(3):893-6.
1991: Sebti S M; Jani J P; Mistry J S; Gorelik E; Lazo J S
Metabolic inactivation: a mechanism of human tumor resistance to bleomycin.
Cancer research 1991;51(1):227-32.
1991: Lazo J S; Sebti S M
Bleomycins.
Cancer chemotherapy and biological response modifiers 1991;12():51-8.
1991: Bahnson R R; Basu A; Lazo J S
The role of metallothioneins in anticancer drug resistance.
Cancer treatment and research 1991;57():251-60.
1990: Weng W L; Lazo J S; Gillis C N; Pitt B R
Disposition of radioiodinated benzylguanidines in perfused rabbit lung: pharmacokinetics and effect of an organo-gold complexed antineoplastic agent.
The Journal of pharmacology and experimental therapeutics 1990;255(1):59-65.
1990: Lazo J S; Hoyt D G
The molecular basis of interstitial pulmonary fibrosis caused by antineoplastic agents.
Cancer treatment reviews 1990;17(2-3):165-7.
1990: Mistry J S; Sebti S M; Lazo J S
Separation of bleomycins and their deamido metabolites by high-performance cation-exchange chromatography.
Journal of chromatography 1990;514(1):86-90.
1990: Hoyt D G; Lazo J S
Bleomycin and cyclophosphamide increase pulmonary type IV procollagen mRNA in mice.
The American journal of physiology 1990;259(2 Pt 1):L47-52.
1990: Basu A; Teicher B A; Lazo J S
Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II).
The Journal of biological chemistry 1990;265(15):8451-7.
1990: Basu A; Lazo J S
A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugs.
Toxicology letters 1990;50(2-3):123-35; discussion 121-2.
1990: Lazo J S; Hoyt D G; Sebti S M; Pitt B R
Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis.
Pharmacology & therapeutics 1990;47(3):347-58.
1990: Lazo J S; Schisselbauer J C; Herring G M; Kennedy K A
Involvement of the cellular vacuolar system with the cytotoxicity of bleomycin-like agents.
Cancer communications 1990;2(2):81-6.
1989: Myers C L; Lazo J S; Pitt B R
Translocation of protein kinase C is associated with inhibition of 5-HT uptake by cultured endothelial cells.
The American journal of physiology 1989;257(4 Pt 1):L253-8.
1989: Lazo J S; Bahnson R R
Pharmacological modulators of DNA-interactive antitumor drugs.
Trends in pharmacological sciences 1989;10(9):369-73.
1989: Sebti S M; Mignano J E; Jani J P; Srimatkandada S; Lazo J S
Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family.
Biochemistry 1989;28(16):6544-8.
1989: Harrison J H; Hoyt D G; Lazo J S
Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice.
Molecular pharmacology 1989;36(2):231-8.
1989: Lazo J S; Schisselbauer J C; Meandzija B; Kennedy K A
Initial single-strand DNA damage and cellular pharmacokinetics of bleomycin A2.
Biochemical pharmacology 1989;38(13):2207-13.
1989: Hoyt D G; Lazo J S
Early increases in pulmonary mRNA encoding procollagens and transforming growth factor-beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis.
The Journal of pharmacology and experimental therapeutics 1989;249(1):38-43.
1989: Sebti S M; DeLeon J C; Ma L T; Hecht S M; Lazo J S
Substrate specificity of bleomycin hydrolase.
Biochemical pharmacology 1989;38(1):141-7.
1989: Lazo J S; Braun I D; Labaree D C; Schisselbauer J C; Meandzija B; Newman R A; Kennedy K A
Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
Cancer research 1989;49(1):185-90.
1989: Hacker M P; Lazo J S; Pritsos C A; Tritton T R
Immobilized adriamycin: toxic potential in vivo and in vitro.
Selective cancer therapeutics 1989;5(2):67-72.
1989: Hait W N; Morris S; Lazo J S; Figlin R J; Durivage H J; White K; Schwartz P E
Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine.
Cancer chemotherapy and pharmacology 1989;23(6):358-62.
1988: Harrison J H; Lazo J S
Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis.
The Journal of pharmacology and experimental therapeutics 1988;247(3):1052-8.
1988: Kelley S L; Basu A; Teicher B A; Hacker M P; Hamer D H; Lazo J S
Overexpression of metallothionein confers resistance to anticancer drugs.
Science (New York, N.Y.) 1988;241(4874):1813-5.
1988: Hoyt D G; Lazo J S
Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice.
The Journal of pharmacology and experimental therapeutics 1988;246(2):765-71.
1988: Hait W N; Lazo J S; Chen D L; Gallichio V S; Filderman A E
Antitumor and toxic effects of combination chemotherapy with bleomycin and a phenothiazine anticalmodulin agent.
Journal of the National Cancer Institute 1988;80(4):246-50.
1988: Filderman A E; Genovese L A; Lazo J S
Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice.
Biochemical pharmacology 1988;37(6):1111-6.
1988: Sebti S M; Lazo J S
Metabolic inactivation of bleomycin analogs by bleomycin hydrolase.
Pharmacology & therapeutics 1988;38(3):321-9.
1987: Harrison J H; Lazo J S
High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis.
The Journal of pharmacology and experimental therapeutics 1987;243(3):1185-94.
1987: MacLusky N J; Voit R; Lazo J S; Schwartz P E; Merino M J; Eisenfeld A E; Naftolin F
Aromatase activity in human ovarian cancer.
Steroids 1987;50(4-6):423-33.
1987: Sebti S M; DeLeon J C; Lazo J S
Purification, characterization, and amino acid composition of rabbit pulmonary bleomycin hydrolase.
Biochemistry 1987;26(14):4213-9.
1987: Sebti S M; Lazo J S
Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidases.
Biochemistry 1987;26(2):432-7.
1986: Mackie K; Lai Y; Nairn A C; Greengard P; Pitt B R; Lazo J S
Protein phosphorylation in cultured endothelial cells.
Journal of cellular physiology 1986;128(3):367-74.
1986: Kennedy K A; Hait W N; Lazo J S
Chemical modulation of bleomycin induced toxicity.
International journal of radiation oncology, biology, physics 1986;12(8):1367-70.
1986: Lazo J S; Lynch T J; McCallister J
Bleomycin inhibition of angiotensin-converting enzyme activity from serum, lungs, and cultured pulmonary artery endothelial cells.
The American review of respiratory disease 1986;134(1):73-8.
1986: Lazo J S
Endothelial injury caused by antineoplastic agents.
Biochemical pharmacology 1986;35(12):1919-23.
1986: Hait W N; Lazo J S
Calmodulin: a potential target for cancer chemotherapeutic agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(6):994-1012.
1986: Lazo J S; Chen D L; Gallicchio V S; Hait W N
Increased lethality of calmodulin antagonists and bleomycin to human bone marrow and bleomycin-resistant malignant cells.
Cancer research 1986;46(5):2236-40.
1986: Teicher B A; Lazo J S; Merrill W W; Filderman A E; Rose C M
Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin.
Cancer chemotherapy and pharmacology 1986;18(3):213-8.
1985: Lazo J S; Schwartz P E
Rapid distribution of adriamycin in the ascitic and pleural fluid of women with ovarian carcinomas.
Gynecologic oncology 1985;21(1):65-72.
1985: Lazo J S; Braun I D; Meandzija B; Kennedy K A; Pham E T; Smaldone L F
Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells.
Cancer research 1985;45(5):2103-9.
1985: Lazo J S; Hacker M P
Organ-directed toxicology of antitumor agents. Symposium summary.
Federation proceedings 1985;44(7):2335-8.
1985: Lazo J S; Hait W N; Kennedy K A; Braun I D; Meandzija B
Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists.
Molecular pharmacology 1985;27(3):387-93.
1984: Lazo J S; Merrill W W; Pham E T; Lynch T J; McCallister J D; Ingbar D H
Bleomycin hydrolase activity in pulmonary cells.
The Journal of pharmacology and experimental therapeutics 1984;231(3):583-8.
1984: Lazo J S; Schwartz P E; MacLusky N J; Labaree D C; Eisenfeld A J
Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro.
Cancer research 1984;44(6):2265-71.
1984: Lazo J S; Pham E T
Pulmonary fate of [3H]bleomycin A2 in mice.
The Journal of pharmacology and experimental therapeutics 1984;228(1):13-8.
1983: Catravas J D; Lazo J S; Dobuler K J; Mills L R; Gillis C N
Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits.
The American review of respiratory disease 1983;128(4):740-6.
1983: Lazo J S; Catravas J D; Dobuler K J; Gillis C N
Prolonged reduction in serum angiotensin converting enzyme activity after treatment of rabbits with bleomycin.
Toxicology and applied pharmacology 1983;69(2):276-82.
1983: Lazo J S; Humphreys C J
Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity.
Proceedings of the National Academy of Sciences of the United States of America 1983;80(10):3064-8.
1982: Lazo J S; Boland C J; Schwartz P E
Bleomycin hydrolase activity and cytotoxicity in human tumors.
Cancer research 1982;42(10):4026-31.
1982: Lee M H; Lazo J S; Li C D; Hadfield A F; Maniglia C A; Sartorelli A C
Solubilization of murine melanoma xylosyltransferase and galactosyltransferase activities and their inactivation by dialdehyde nucleosides.
Chemico-biological interactions 1982;41(2):141-53.
1981: Lazo J S; Catravas J D; Gillis C N
Reduction in rabbit serum and pulmonary angiotensin converting enzyme activity after subacute bleomycin treatment.
Biochemical pharmacology 1981;30(18):2577-84.
1981: Lazo J S
Angiotensin converting enzyme activity in mice after subacute bleomycin administration.
Toxicology and applied pharmacology 1981;59(2):395-404.
1981: Catravas J D; Lazo J S; Gillis C N
Biochemical markers of bleomycin toxicity: clearance of [14C]-5-hydroxytryptamine and [3H]norepinephrine by rabbit lung in vivo.
The Journal of pharmacology and experimental therapeutics 1981;217(2):524-9.
1981: Teicher B A; Lazo J S; Sartorelli A C
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.
Cancer research 1981;41(1):73-81.
1980: Lazo J S; Quinn D E
Solubilization of pulmonary angiotensin-converting enzyme with 1-O-n-octyl-beta-D-glucopyranoside.
Analytical biochemistry 1980;102(1):68-71.
1979: Lazo J S; Shansky C W; Sartorelli A C
Reduction in cell surface concanavalin A binding and mannose incorporation into glycoproteins of sarcoma 180 by 6-thioguanine.
Biochemical pharmacology 1979;28(5):583-8.
1978: Lazo J S; Ingber D E; Sartorelli A C
Enhancement of experimental lung metastases by cultured B16 melanoma cells treated with (+/-)-1,2-bis(3,5-dioxopiperazin-1-y)propane (ICRF-159).
Cancer research 1978;38(8):2263-70.
1977: Lazo J S; Hwang K M; Sartorelli A C
Inhibition of L-fucose incorporation into glycoprotein of Sarcoma 180 ascites cells by 6-thioguanine.
Cancer research 1977;37(12):4250-5.
1977: Lazo J S; Ruddon R W
Neurite extension and malignancy of neuroblastoma cells after treatment with prostaglandin E1 and papaverine.
Journal of the National Cancer Institute 1977;59(1):137-43.
1976: Lazo J S; Prasad K N; Ruddon R W
Synthesis and phosphorylation of chromatin-associated proteins in cAMP-induced "differentiated" neuroblastoma cells in culture.
Experimental cell research 1976;100(1):41-6.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

John Lazo

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Disorders

Concepts & Ideas

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of John Lazo (preview)

All Publications